Vimentin Antibody - #AF0292

(6)   (9)  
Product: Vimentin Antibody
Catalog: AF0292
Description: Rabbit polyclonal antibody to Vimentin
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 53kDa; 54kD(Calculated).
Uniprot: P08670
RRID: AB_2833458

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
Vimentin Antibody detects endogenous levels of total Vimentin.
RRID:
AB_2833458
Cite Format: Affinity Biosciences Cat# AF0292, RRID:AB_2833458.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; Vimentin;

Immunogens

Immunogen:
Uniprot:

P08670(VIME_HUMAN) >>Visit HPA database.

Gene(ID):
VIM(7431)
Expression:
P08670 VIME_HUMAN:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

Description:
vimentin an intermediate filament protein. Intermediate filament proteins are expressed in a tissue-specific manner. Desmin is the subunit specific for muscle and vimentin the subunit specific for mesenchymal tissue.
Sequence:
MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Horse
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P08670 As Substrate

Site PTM Type Enzyme
S2 Phosphorylation
T3 Phosphorylation
R4 Methylation
S5 Phosphorylation P17252 (PRKCA)
S7 O-Glycosylation
S7 Phosphorylation P17252 (PRKCA) , Q96GD4 (AURKB) , Q02156 (PRKCE) , P17612 (PRKACA)
S8 Phosphorylation P17252 (PRKCA)
S9 Phosphorylation P17252 (PRKCA)
S10 Phosphorylation P17252 (PRKCA)
Y11 Phosphorylation
R12 Methylation
R13 Methylation
T20 Phosphorylation
S22 Phosphorylation
R23 Methylation
S25 Phosphorylation P17252 (PRKCA) , Q96GD4 (AURKB) , P17612 (PRKACA)
S26 Phosphorylation Q13153 (PAK1) , P17252 (PRKCA) , Q13177 (PAK2)
S27 Phosphorylation
R28 Methylation
S29 Phosphorylation
Y30 Phosphorylation
T32 Phosphorylation
T33 O-Glycosylation
T33 Phosphorylation
S34 O-Glycosylation
S34 Phosphorylation P17252 (PRKCA)
T35 Phosphorylation
R36 Methylation
T37 Phosphorylation
Y38 Phosphorylation
S39 Phosphorylation P49137 (MAPKAPK2) , Q13177 (PAK2) , P17612 (PRKACA) , O75116 (ROCK2) , P31749 (AKT1) , Q13153 (PAK1) , Q96GD4 (AURKB) , P17252 (PRKCA)
S42 Phosphorylation P17252 (PRKCA)
R45 Methylation
S47 Phosphorylation P17612 (PRKACA) , Q96GD4 (AURKB)
T48 Phosphorylation
S49 Phosphorylation
R50 Methylation
S51 Phosphorylation Q13177 (PAK2) , Q13153 (PAK1) , P49137 (MAPKAPK2)
Y53 Phosphorylation
S55 O-Glycosylation
S55 Phosphorylation P24941 (CDK2) , P06493 (CDK1)
S56 Phosphorylation P78527 (PRKDC) , P06493 (CDK1) , P49137 (MAPKAPK2) , Q13153 (PAK1) , P24941 (CDK2) , Q00535 (CDK5)
Y61 Phosphorylation
T63 Phosphorylation
R64 Methylation
S65 Phosphorylation Q96GD4 (AURKB)
S66 Phosphorylation Q96GD4 (AURKB) , Q13177 (PAK2) , Q13153 (PAK1)
R69 Methylation
R71 Methylation
S72 Phosphorylation P17612 (PRKACA) , Q96GD4 (AURKB) , Q13464 (ROCK1) , O75116 (ROCK2)
S73 Phosphorylation Q13177 (PAK2) , Q96GD4 (AURKB) , P17612 (PRKACA) , Q13153 (PAK1)
S83 Phosphorylation Q13557 (CAMK2D) , Q9UQM7 (CAMK2A) , P49137 (MAPKAPK2) , P53350 (PLK1)
S87 Phosphorylation Q96GD4 (AURKB)
K97 Ubiquitination
T99 Phosphorylation
T101 Phosphorylation
K104 Acetylation
K104 Ubiquitination
R113 Methylation
Y117 Phosphorylation
K120 Acetylation
K120 Methylation
K120 Ubiquitination
K129 Acetylation
K129 Ubiquitination
K139 Acetylation
K139 Ubiquitination
K143 Ubiquitination
S144 Phosphorylation
Y150 Phosphorylation
R158 Methylation
K168 Acetylation
K168 Ubiquitination
R184 Methylation
K188 Ubiquitination
T202 Phosphorylation
S205 Phosphorylation
S214 Phosphorylation
K223 Ubiquitination
S226 Phosphorylation
K235 Acetylation
K235 Ubiquitination
K236 Acetylation
K236 Ubiquitination
S261 Phosphorylation
K262 Ubiquitination
T266 Phosphorylation
Y276 Phosphorylation
S278 Phosphorylation
K282 Acetylation
K282 Ubiquitination
Y291 Phosphorylation
K292 Acetylation
K292 Ubiquitination
K294 Acetylation
K294 Ubiquitination
S299 Phosphorylation
R310 Methylation
K313 Acetylation
K313 Sumoylation
K313 Ubiquitination
S316 Phosphorylation
T317 Phosphorylation
S325 Phosphorylation
T327 Phosphorylation
C328 S-Nitrosylation
K334 Acetylation
K334 Ubiquitination
T336 Phosphorylation
S339 Phosphorylation
Y358 Phosphorylation
T361 Phosphorylation
K373 Acetylation
K373 Ubiquitination
R381 Methylation
Y383 Phosphorylation
Y400 Phosphorylation
R401 Methylation
K402 Acetylation
K402 Sumoylation
K402 Ubiquitination
S409 Phosphorylation
R410 Methylation
S412 Phosphorylation
S419 Phosphorylation
S420 Phosphorylation
T426 Phosphorylation
S430 Phosphorylation P78527 (PRKDC)
T436 Phosphorylation
S438 Phosphorylation
K439 Acetylation
K439 Ubiquitination
T441 Phosphorylation
K445 Acetylation
K445 Methylation
K445 Sumoylation
K445 Ubiquitination
T446 Phosphorylation
T449 Phosphorylation
T458 Phosphorylation P00540 (MOS)
S459 Phosphorylation P78527 (PRKDC) , P53350 (PLK1) , P00540 (MOS)

Research Backgrounds

Function:

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.

Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.

PTMs:

Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS.

O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status.

S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

Subcellular Location:

Cytoplasm. Cytoplasm>Cytoskeleton. Nucleus matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

Subunit Structure:

Homopolymer assembled from elementary dimers. Interacts with LGSN and SYNM. Interacts (via rod region) with PLEC (via CH 1 domain) (By similarity). Interacts with SLC6A4. Interacts with STK33. Interacts with LARP6. Interacts with RAB8B (By similarity). Interacts with TOR1A; the interaction associates TOR1A with the cytoskeleton. Interacts with TOR1AIP1. Interacts with BCAS3. Interacts with DIAPH1. Identified in complexes that contain VIM, EZR, AHNAK, BFSP1, BFSP2, ANK2, PLEC, PRX and spectrin (By similarity). Interacts with EPPK1; interaction is dependent of higher-order structure of intermediate filament. Interacts with the non-receptor tyrosine kinase SRMS; the interaction leads to phosphorylation of VIM. Interacts with NOD2. Interacts (via head region) with CORO1C (By similarity). Interacts with HDGF (isoform 2).

(Microbial infection) Interacts with HCV core protein.

Family&Domains:

The central alpha-helical coiled-coil IF rod domain mediates elementary homodimerization.

The [IL]-x-C-x-x-[DE] motif is a proposed target motif for cysteine S-nitrosylation mediated by the iNOS-S100A8/A9 transnitrosylase complex.

Belongs to the intermediate filament family.

Research Fields

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

References

1). Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018 (PubMed: 29530061) [IF=11.3]

Application: WB    Species: human    Sample: CRC

Fig. 2| SCD1 promotes migration and invasion of colorectal cancer cells by regulating EMT. i, j Protein levels of E-cadherin and vimentin in colorectal cancer cells transfected with SCD1 shRNA (i) or SCD1 cDNA (j)
2). Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma. LIVER INTERNATIONAL, 2022 (PubMed: 34854209) [IF=6.7]

Application: WB    Species: Human    Sample: HepG2 and Huh7 cells

FIGURE 7 A, Representative images of the western blot results for uPAR, MMP2 and MMP9 in ALB knockdown HepG2 and Huh7 cells; B, Zymography analysis illustrates MMP2 and MMP9 activity in ALB knockdown HepG2 and Huh7 cells; C, Quantitative analysis results and representative images of the western blot results for the EMT‐associated markers, E‐cadherin, N‐cadherin, vimentin, Snail and Twist by western blot in ALB knockdown HepG2 and Huh7 cells; D, Quantification shows a significantly higher uPAR in HCC group with ALB <3.5 g/dL compared to ALB ≥3.5 g/dL (*P < .05); E, Scatterplot showing the correlation between plasma levels of ALB and uPAR. The vertical position represents the expression levels of uPAR (lg pg/mL)
3). Knockdown of Nucleostemin in an ovarian cancer SKOV-3 cell line and its effects on cell malignancy. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017 (PubMed: 28412352) [IF=3.1]

Application: WB    Species: human    Sample:

Fig. 3. Knockdown of NS inhibited tumor migration and invasion in vitro. (A) Crystal violet staining of the shNS and control group cells that crossed the polycarbonate membrane of the Transwell chamber to detect cell migration. (B) The number of cells that crossed the Transwell migration chamber in different groups. (C) Crystal violet staining of the shNS and control group cells that crossed the Matrigel-coated polycarbonate membrane of the Transwell chamber to detect cell invasion. (D) The number of cells that crossed the Transwell invasion chamber in different groups. (E) Representative Western blotting results indicate the EMT marker expressions in the different groups. The results are presented as the means ± SD, as based on three independent experiments. Statistical significance was determined using Student's t-test. *P < 0.05. Scale: 100 mm.

Application: IHC    Species: human    Sample:

Fig. 4. Knockdown of NS suppressed tumor formation and growth in vivo. (A) The shNS and control group cells were inoculated s.c. into the right flanks of BALB/c nude mice. Tumor volumes were monitored and recorded weekly (n ¼ 3). The results are presented as the means ± SD, as based on three independent experiments. ****P < 0.0001. (B) Examples of the tumors excised from the shNS and control mice on the 19th week following injection. Scale: 2 cm. (C) Immunohistochemistry staining of the tumor sections obtained from mice in the shNS and control groups. Antibodies: NS, Ki-67, cyclin D1, and Vimentin.
4). High glucose induces epithelial-mesenchymal transition and results in the migration and invasion of colorectal cancer cells. Experimental and Therapeutic Medicine, 2018 (PubMed: 29896243) [IF=2.7]
5). High CCL7 expression is associated with migration, invasion and bone metastasis of non-small cell lung cancer cells. American Journal of Translational Research, 2019 (PubMed: 30788000) [IF=2.2]

Application: WB    Species: mouse    Sample: A549 and PC9 cells

Figure 4. |CCL7 induces EMT in A549 and PC9 cells via interacting with CCR3. A. Protein expression of CCR1, CCR2 and CCR3 in A549 and PC9 cells with different doses of recombinant CCL7 (100 ng/ml, 200 ng/ml); the result showed that CCL7 had no effect on the expression of CCR. B-D. Wound healing assay and transwell invasion assay of A549 and PC9 cells after co-incubation with recombinant CCL7 and CCR inhibitors respectively; interestingly, inhibition of CCR3 significantly suppressed cell invasion. E. CCL7 increased the expression of mesenchymal markers and decreased the expression of epithelial markers in A549 and PC9 cells via CCR3.
6). Doxycycline directly targets PAR1 to suppress tumor progression. Oncotarget, 2017 (PubMed: 28187433)

Application: IHC    Species: human    Sample:

(F) Immunohistochemical staining to identify EMT biomarkers and doxycycline inhibited proteins in treated and untreated cells. Doxycycline-treated cells display stronger E-cadherin and α-SMA staining but reduced vimentin,MMP-2 and MMP-9 staining;

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.